Hyper-expensive new therapies and the prioritisation of R&D

This background paper - produced for the Nuffield Council on Bioethics Forward Look Seminar 2011 - provides a summary of the ethical arguments and policy issues which arise in considering very expensive medical treatments and their place within a fixed healthcare budget such as the NHS.